| scholarly article | Q13442814 |
| P50 | author | Alexander Goesmann | Q52422599 |
| Paul M Howley | Q118516896 | ||
| P2093 | author name string | Lutz Krause | |
| Sebastian Konietzny | |||
| Michaela Schmidt | |||
| Jürgen Hausmann | |||
| Paul Chaplin | |||
| Burkhard Linke | |||
| Mark Suter | |||
| Susanne Lukassen | |||
| Christine Meisinger-Henschel | |||
| P433 | issue | Pt 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Vaccinia virus | Q1986297 |
| P304 | page(s) | 3249-3259 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Journal of General Virology | Q6295245 |
| P1476 | title | Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara | |
| P478 | volume | 88 |
| Q36315441 | A cross-species view on viruses |
| Q34952043 | A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses |
| Q24276422 | A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model |
| Q33624420 | A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. |
| Q33957049 | A single vertebrate DNA virus protein disarms invertebrate immunity to RNA virus infection |
| Q37209483 | Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants |
| Q34171543 | Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes |
| Q27008256 | Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination |
| Q58764039 | Characterization of indels in poxvirus genomes |
| Q47552501 | Characterizing the effects of insertion of a 5.2 kb region of a VACV genome, which contains known immune evasion genes, on MVA immunogenicity |
| Q38092470 | Clinical development of Modified Vaccinia virus Ankara vaccines |
| Q36947039 | Deletion of A44L, A46R and C12L Vaccinia Virus Genes from the MVA Genome Improved the Vector Immunogenicity by Modifying the Innate Immune Response Generating Enhanced and Optimized Specific T-Cell Responses. |
| Q35076706 | Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice |
| Q34810232 | Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching |
| Q37643731 | Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. |
| Q103803963 | Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform |
| Q96030198 | Early smallpox vaccine manufacturing in the United States: Introduction of the "animal vaccine" in 1870, establishment of "vaccine farms", and the beginnings of the vaccine industry |
| Q38970262 | Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara. |
| Q38176419 | Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors |
| Q91258220 | Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle |
| Q37332861 | Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. |
| Q92531070 | Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems |
| Q34593862 | Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response. |
| Q41842760 | Genome comparison of a nonpathogenic myxoma virus field strain with its ancestor, the virulent Lausanne strain. |
| Q37944321 | Innate immune recognition of poxviral vaccine vectors |
| Q37779516 | Interaction of orthopoxviruses with the cellular ubiquitin-ligase system. |
| Q34120696 | Introduction of the Six Major Genomic Deletions of Modified Vaccinia Virus Ankara (MVA) into the Parental Vaccinia Virus Is Not Sufficient To Reproduce an MVA-Like Phenotype in Cell Culture and in Mice |
| Q27025941 | Matrix and backstage: cellular substrates for viral vaccines |
| Q35634159 | Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs |
| Q37067250 | Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge |
| Q84089780 | Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain |
| Q35151746 | Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway |
| Q34641590 | Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation. |
| Q41931134 | Organism-Level Analysis of Vaccination Reveals Networks of Protection across Tissues. |
| Q21285044 | Orthopoxvirus genes that mediate disease virulence and host tropism |
| Q28712008 | Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses |
| Q38092468 | Recombinant MVA vaccines: dispelling the myths |
| Q36679394 | Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity |
| Q38741327 | Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. |
| Q34594898 | Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses. |
| Q89531655 | Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells |
| Q92404259 | SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells |
| Q36846282 | Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial. |
| Q36532515 | Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection |
| Q49377121 | Swinepox virus vector-based vaccines: attenuation and biosafety assessments following subcutaneous prick inoculation |
| Q100736394 | The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform |
| Q37909421 | The strategic use of novel smallpox vaccines in the post-eradication world. |
| Q35826480 | The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence |
| Q38620980 | Use of functional genomics to understand replication deficient poxvirus-host interactions |
| Q35571248 | Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. |
| Q52680807 | Virulent poxviruses inhibit DNA sensing by preventing STING activation. |
| Q99633776 | Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells |
Search more.